BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 20647563)

  • 1. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
    From AM; Al Badarin FJ; McDonald FS; Bartholmai BJ; Cha SS; Rihal CS
    Circ Cardiovasc Interv; 2010 Aug; 3(4):351-8. PubMed ID: 20647563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
    Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials.
    Han XF; Zhang XX; Liu KM; Tan H; Zhang Q
    PLoS One; 2018; 13(3):e0194330. PubMed ID: 29558481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
    Zhang J; Jiang Y; Rui Q; Chen M; Zhang N; Yang H; Zhou Y
    Medicine (Baltimore); 2018 May; 97(18):e0617. PubMed ID: 29718868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media.
    McCullough PA; Bertrand ME; Brinker JA; Stacul F
    J Am Coll Cardiol; 2006 Aug; 48(4):692-9. PubMed ID: 16904536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the risk of total cardiovascular events of isosmolar iodixanol compared with low-osmolar contrast media.
    Zhang BC; Wu Q; Wang C; Li DY; Wang ZR
    J Cardiol; 2014 Apr; 63(4):260-8. PubMed ID: 24397991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
    Liss P; Persson PB; Hansell P; Lagerqvist B
    Kidney Int; 2006 Nov; 70(10):1811-7. PubMed ID: 17003814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
    Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
    Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Eng J; Wilson RF; Subramaniam RM; Zhang A; Suarez-Cuervo C; Turban S; Choi MJ; Sherrod C; Hutfless S; Iyoha EE; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):417-24. PubMed ID: 26830055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-induced nephropathy in outpatients with preexisting renal impairment: a comparison between intravenous iohexol and iodixanol.
    Cernigliaro JG; Haley WE; Adolphson DP; Jepperson MA; Crook JE; Thomas CS; Parker AS
    Clin Imaging; 2016; 40(5):902-6. PubMed ID: 27183138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
    EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent clinical trials of iodixanol.
    Erdogan A; Davidson CJ
    Rev Cardiovasc Med; 2003; 4 Suppl 5():S43-50. PubMed ID: 14668709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy.
    Adolph E; Holdt-Lehmann B; Chatterjee T; Paschka S; Prott A; Schneider H; Koerber T; Ince H; Steiner M; Schuff-Werner P; Nienaber CA
    Coron Artery Dis; 2008 Sep; 19(6):413-9. PubMed ID: 18955835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease.
    Tadros GM; Malik JA; Manske CL; Kasiske BL; Dickinson SE; Herzog CA; Wilson RF; Das G; Panetta CJ
    J Invasive Cardiol; 2005 Apr; 17(4):211-5. PubMed ID: 15831975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.